ARIES研究:阿柏西普治疗延长方案对新生血管性AMD的疗效与安全性
结果显示两组从随机化到第104周的最佳矫正视力变化非劣效,注射次数相差1次,安全性和解剖学结果相似。
要点
- 早期与晚期启动T&E方案在视力变化上非劣效,2年内注射次数仅差1次。
- 两组从基线到第104周分别有93.4%和96.2%患者维持视力。
- 第104周时,早期组和晚期组分别有47.2%和51.9%患者注射间隔≥12周。
核心结论
- 对于新生血管性AMD患者,阿柏西普早期启动T&E与晚期启动T&E在视力结果上非劣效,且注射次数相近,整体结果相似。
研究设计与样本
- 患者在第0、4、8、16周接受2mg玻璃体内阿柏西普注射,第16周按1:1随机分为早期启动T&E(每2周调整间隔)或晚期启动T&E(每8周调整直至第48周后每2周调整)。
- 主要终点为随机化至第104周的最佳矫正视力变化。
主要发现
- 第16-104周平均(SD)最佳矫正视力变化:早期T&E组-2.1(11.4)字母,晚期T&E组-0.4(8.4)字母,最小二乘均数差-2.0(95%CI:-4.75至0.71),非劣效P=0.0162。
- 第0-104周平均(SD)最佳矫正视力变化:早期T&E组+4.3(13.4)字母,晚期T&E组+7.9(11.9)字母。
- 平均(SD)注射次数:早期T&E组12.0(2.3)次,晚期T&E组13.0(1.8)次。
- 从基线至第104周,早期T&E组和晚期T&E组分别有93.4%和96.2%患者维持最佳矫正视力;平均(SD)中心视网膜厚度变化分别为-161.6(135.6)µm和-158.6(125.1)µm。
- 第104周最后一次注射间隔≥12周的患者比例:早期T&E组47.2%,晚期T&E组51.9%。
关键数值与推荐
- 非劣效界值未在原文摘要中报告。
- 早期启动T&E定义为每2周调整间隔;晚期启动T&E定义为每8周调整直至第48周,之后每2周调整。
- 主要终点非劣效检验P=0.0162。
临床怎么用
- 临床中对于新生血管性AMD,阿柏西普早期启动T&E方案(第16周开始每2周调整间隔)与晚期启动T&E方案(第48周前每8周调整)均可采用,两者视力结局和注射负担相近。
局限性
- 研究为开放标签设计,可能存在偏倚。
- 随访时间为104周,长期结果未报告。
- 非劣效界值未在摘要中明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/PURPOSE: Treating neovascular age-related macular degeneration with intravitreal aflibercept treat-and-extend (T&E) can reduce treatment burden. ARIES assessed whether intravitreal aflibercept early-start T&E was noninferior to late-start T&E. METHODS: A randomized, open-label, Phase 3b/4 study that included treatment-naïve patients aged ≥50 years with the best-corrected visual acuity 73-25 Early Treatment Diabetic Retinopathy Study letters and active choroidal neovascularization secondary to AMD. Patients received 2 mg intravitreal aflibercept at Week (W) 0, W4, W8, and W16. At W16, patients were randomized 1:1 to early-start (2W interval adjustments) or late-start T&E (8W intervals until W48 then 2W interval adjustments). Primary endpoint: the best-corrected visual acuity change from randomization to W104. RESULTS: Two-hundred seventy-one patients were randomized. The mean (SD) best-corrected visual acuity at baseline was 60.2 (12.1; early-T&E) and 61.3 (10.8; late-T&E) letters. The mean (SD) best-corrected visual acuity change (W16-104) was -2.1 (11.4) versus -0.4 (8.4) letters (early-T&E vs. late-T&E; least-squares mean difference: -2.0; 95% confidence interval: -4.75 to 0.71; P = 0.0162 for noninferior); +4.3 (13.4) versus +7.9 (11.9) letters (W0-104). The mean (SD) number of injections was 12.0 (2.3) versus 13.0 (1.8). From baseline to W104, 93.4% and 96.2% maintained best-corrected visual acuity; the mean (SD) central retinal thickness change was -161.6 (135.6) µm and -158.6 (125.1) µm. The last injection interval (W104) was ≥12W for 47.2% and 51.9% of patients. CONCLUSION: Outcomes were similar between patients with neovascular age-related macular degeneration treated with an intravitreal aflibercept early-T&E or late-T&E regimen after initial dosing, with one injection difference over 2 years. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02581891 https://clinicaltrials.gov/ct2/show/NCT02581891. Supplemental Digital Contents (files 1 http://links.lww.com/IAE/B419).
引用
- Mitchell P, Holz FG, Hykin P, et al. EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT USING A TREAT-AND-EXTEND REGIMEN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: The ARIES Study: A Randomized Clinical Trial. Retina. 2021. PMID: 33782365. doi:10.1097/IAE.0000000000003128
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。